# Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma

> **NCT00410605** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 39 (actual)

## Conditions studied

- Multiple Myeloma in Relapse
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** lenalidomide
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT00410605
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2011-12
- **Final completion:** 2014-06
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2017-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00410605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00410605, "Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00410605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*